CorMedix(CRMD) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's portfolio contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025 [17] - The operating expenses for Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure post-Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis, especially as reimbursement transitions to a bundled add-on mechanism starting July 1, 2026 [6][7] - The guidance for DefenCath in 2026 is set at $150 million-$170 million, with 2027 guidance at $100 million-$125 million [6][8] Company Strategy and Development Direction - The acquisition of Melinta Therapeutics is seen as a significant growth opportunity, adding durable products like MINOCIN and VABOMERE to the portfolio [11] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [9] - 2026 is expected to be a transitional year, with a focus on new catalysts and value drivers, particularly the phase 3 ReSPECT data for REZZAYO [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the post-TDAPA environment and maintain growth through strategic pricing and customer negotiations [6][23] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price [7] Other Important Information - The company has expanded its workforce significantly, growing from approximately 100 to just under 200 employees, to support growth and operational needs [17] - The company has initiated a share repurchase program, indicating confidence in its financial position and future growth prospects [21] Q&A Session Summary Question: Update on dialysis customer conversations and pricing for DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and beyond [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted that the data will guide commercial utility and marketing strategies, with a focus on pathogen data and secondary endpoints [24][25] Question: Developments on TDAPA extension bills and partnerships - Management noted ongoing efforts with legislators and other companies, but timing remains uncertain due to external factors [29][30] Question: Inpatient opportunity with DefenCath and Melinta product growth - Management discussed the current customer mix and potential growth from mid-sized operators, emphasizing the importance of onboarding new customers [33][41]